Bachtarzi Houria, Stevenson Mark, Fisher Kerry
University of Oxford, Department of Clinical Pharmacology, Old Road Campus Research Building, OX3 7DQ, Oxford, UK.
Expert Opin Drug Deliv. 2008 Nov;5(11):1231-40. doi: 10.1517/17425240802507636.
Clinical experience with adenovirus vectors has highlighted the need for improved delivery and targeting.
This manuscript aims to provide an overview of the techniques currently under development for improving adenovirus delivery to malignant cells in vivo.
Primary research articles reporting improvements in adenoviral gene delivery are described. Strategies include genetic modification of viral coat proteins, non-genetic modifications including polymer encapsulation approaches and pharmacological interventions.
RESULTS/CONCLUSION: Reprogramming adenovirus tropism in vitro has been convincingly demonstrated using a range of genetic and physical strategies. These studies have provided new insights into our understanding of virology and the field is progressing. However, there are still some limitations that need special consideration before adenovirus-targeted cancer gene therapy emerges as a routine treatment in the clinical setting.
腺病毒载体的临床经验凸显了改进递送和靶向性的必要性。
本手稿旨在概述目前正在开发的用于改善腺病毒在体内向恶性细胞递送的技术。
描述了报道腺病毒基因递送改进的主要研究文章。策略包括病毒衣壳蛋白的基因修饰、非基因修饰（包括聚合物封装方法和药理学干预）。
结果/结论：使用一系列遗传和物理策略已令人信服地证明了在体外对腺病毒嗜性进行重新编程。这些研究为我们对病毒学的理解提供了新的见解，该领域正在取得进展。然而，在腺病毒靶向癌症基因治疗成为临床常规治疗方法之前，仍有一些局限性需要特别考虑。
